Pieris Pharmaceuticals, a clinical-stage biopharmaceutical company, has developed a series of Anticalin-based drugs that have shown promising results in the treatment of various ailments. The company's Anticalin proteins are low molecular-weight therapeutic proteins derived from lipocalins. These naturally occurring low-molecular weight human proteins are found in human blood plasma and other bodily fluids. Pieris Pharmaceuticals' lead respiratory Anticalin-based drug candidate, elarekibep, is being used for the treatment of asthma. Additionally, the company has PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. Recently, the company has been developing PRS-344/S09501, a drug candidate consisting of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. The company boasts several partnership agreements with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc. They also have license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals was incorporated in 2000 and is headquartered in Boston, Massachusetts. The company's unique approach to developing Anticalin-based drugs has garnered attention in the biopharmaceutical industry and may hold the potential for meaningful advancements in treating various diseases.
Pieris Pharmaceuticals's ticker is PIRS
The company's shares trade on the NASDAQ stock exchange
They are based in Boston, Massachusetts
There are 51-200 employees working at Pieris Pharmaceuticals
It is pieris.com
Pieris Pharmaceuticals is in the Healthcare sector
Pieris Pharmaceuticals is in the Biotechnology industry
The following five companies are Pieris Pharmaceuticals's industry peers: